Full Press Release Details
Pharmaceuticals Announces Acquisition of Pharmacy Creations,
Company to Make and Distribute its Patent-Pending Proprietary Formulations
marks important milestone as company approaches
launch targeting ophthalmologists-
DIEGO, February 11, 2014/PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused
on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that
it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art
compounding pharmacy located in Randolph, New Jersey. This acquisition would permit the Company to make and distribute its patent-pending
proprietary drug formulations and other novel pharmaceutical solutions.
Pharmaceuticals and the team at Pharmacy Creations have been working together since last summer when the Company became aware
of and subsequently acquired the intellectual property for its suite of ophthalmic formulations from Pharmacy Creations'
co-founders, Scott Karolchyk, MS, RPh, DNM, FIACP and Bernard Covalesky, MS, RPh.
believe this acquisition represents a critical stepping stone toward achieving our vision of building a national footprint able
to deliver our proprietary and other novel formulations to Americans. Even more than the physical Pharmacy Creations facility,
we are ecstatic to have their incredibly skilled and knowledgeable employees join the Imprimis Team," said Imprimis CEO
Mark L. Baum. "After extensive diligence, we believe the acquisition of Pharmacy Creations will support our mission to solve
unmet patient needs through the development and commercialization of proprietary and novel sterile drug formulations. Importantly,
this transaction will also bring new and exciting intellectual property assets to Imprimis that we expect to add value to our
business, particularly in ophthalmology."
team is thrilled to join Imprimis and collectively build on our shared values of integrity, innovation, safety, quality and evidence-based
development. Together, we believe that Imprimis and Pharmacy Creations are going to raise the bar and set a higher standard in
quality and innovation," stated Bernard Covalesky, Pharmacy Creations co-founder.
been in the healthcare field for nearly 30 years and strongly believe that Imprimis Pharmaceuticals and its innovative approach
and unique business model have the potential to revolutionize the way the market approaches personalized medicine. Collaboration
with physicians and pharmacists can produce incredible innovation. The ability to take that innovation, validate it and make it
available to the market quickly - for the benefit of patients and physicians - is powerful," added Scott Karolchyk, Pharmacy
Creations co-founder.
Creations was established nearly 15 years ago and has created a deep formulation portfolio, well-established relationships and
a dedicated and tenured staff. Through an unrelenting focus on meeting physician and patient needs, Pharmacy Creations now achieves
multi-million dollar annual revenues.
transaction is expected to close on or before March 31, 2014, subject to the satisfaction of certain customary closing conditions.
Additional details can be found in the Company's 8-K filing (www.sec.gov).
IMPRIMIS PHARMACEUTICALS
Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and
commercialization of proprietary and novel sterile and topical drug formulations. Imprimis' patent-pending drug formulations
are available today and are being prescribed by physicians. For more information, please visit www.imprimispharma.com or
Creations is a leading provider of customized medication solutions in the United States. All compounds are prepared on order or
prescription from a physician. Pharmacists Scott Karolchyk and Bernard Covalesky along with the staff of professionals at Pharmacy
Creations are committed to compassionate, professional patient care. For more information, please visit: www.pharmacycreations.com.
press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward
looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results
to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could
cause actual results to differ from those predicted include risks and uncertainties arising from the possibility that the closing
of the transaction may be delayed or may not occur, difficulties with the integration process or the realization of the expected
benefits of the transaction, Imprimis' ability to acquire, develop, commercialize and market new formulations and technologies,
enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations
for the development and distribution of its formulations, commercialize its formulations and technologies, obtain intellectual
property protection for its assets, accurately estimate its expenses and cash burn, and raise additional funds, as well as risks
related to additional research and development activities related to its formulations and technologies, the projected size of
the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market
developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry, competition and market
conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read
free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements,
which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward
looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.